ClinicalTrials.gg
RecruitingNCT06890169OneSTOPUpdated Mar 21, 2025

OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities

An interventional study of OneSTOP program and Standard of care weight management program in Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease and Hypertension, sponsored by Changi General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Changi General Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Obesity with a site in Singapore — 17 open to participants now, 25 under way, 1 of them phase 3. Obesity · Singapore.

Planned enrollment
20th of 68
120 · median 70
Started
2025
with 7 others
No phase
44 of 83
9 open now
Primary completion
2027-02
later than 15 of 24 live
Registered
64th of 83
by date
Lead sponsor
4 of 83
Changi General Hospital

Among the 83 studies in Obesity with a site in Singapore, this one is the 20th largest by planned enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2025, is one of 44 with no phase, reaches primary completion later than 15 of the 24 other live ones, and was the 64th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

17 of the 83 studies in Obesity with a site in Singapore are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Obesity with a site in Singapore, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).

Researchers will compare this model with the conventional standard of care of physical visit-based weight management program to see if this model is non-inferior to the standard of care for inducing weight loss, and if there is greater patient convenience with telehealth and more frequent self-monitoring, compliance with diet advice and exercise participation compared to standard of care.

Participants in the standard arm will attend 4 physical doctor and 4 physical dietician consultations over 26 weeks, where they will be provided with an individualized diet and exercise prescription to induce at least 5% weight loss.

Participants in the intervention arm will have the same number of consults over 26 weeks, of which at least 50% will be teleconsults, and will also be provided with an individualized diet and exercise prescription to induce at least 5% weight loss. In addition, they will be taught to use the EMPOWER app to upload weight, blood pressure and glucose, food and exercise records which will be reviewed at the consults. The app also delivers nudges to improve adherence to lifestyle modification.

Read the detailed description

Design This a randomized controlled study comparing a standard weight management program of face-to-face (F2F) consults with doctors (endocrinologists and sports medicine physicians) and dieticians as defined by best-practice guidelines (control), or to the OneSTOP (One-Stop Telecare Obesity Program) a novel weight management intervention incorporating telecare and the EMPOWER app jointly developed by SingHealth and the NUS School of Computing.

Standard of care (control) The standard F2F structured weight management program consists of 4 doctor and 4 dietician consults over 26 weeks, at 2-4 weekly intervals in the first 3 months, and 6-8 weeks in the next 3 months. At the baseline visit, participants are provided with an aerobic and resistance exercise prescription individualized to each subject's fitness and comorbidities to target at least 180 minutes/week of moderate-intensity physical activity (with exercise on at least 3 days/week), and dietary advice based on a calorie-deficit diet (400-600 kilocalories less than the calculated daily caloric requirement, based on the Mifflin-St Jeor equation) which emphasizes reduction in sugar-sweetened beverages, refined carbohydrates and saturated fats. Subjects will be provided with a list of fitness resources such as gyms and fitness corners with advice on use of the equipment, and specific guidance on increasing intensity and duration of exercise and monitoring for injury. Dietary advice will be based on standard guidelines to target a calorie-deficit of 400-600 kcal from baseline. All subjects will keep food diaries and records of exercise duration for review and will also be provided with links to online resources for health advice and generic apps to track their calorie intake and physical activity. At each visit, exercise and diet records and/or results of investigations will be reviewed, and lifestyle advice modified to target at least 5% weight loss.

Intervention This will incorporate at least 50% (4 out of 8 sessions) of the doctor and dietician consults over the 26-week study as teleconsults, which may be scheduled as joint or asynchronous consults. The exercise prescription will likewise be tailored to each subject's individual needs as in the F2F structured weight management program in the control group, and similar dietary advice and reviews will be provided. In addition, participants will be taught to use the EMPOWER app will be used to enable them to upload their weight, blood pressure and glucose, food and exercise duration records. The app also has the capability to co-ordinate visits and investigations, deliver intelligent health nudges and reminders on adherence to treatment which can be individualized to their progress, and provide information on their conditions with additional information curated by their doctors and dieticians. Subjects will be able to compare the photos of their food with that in a database on the app, which will make calorie counting more precise. The app will also be paired with an activity tracker for more accurate estimates of exercise duration. Similar to the standard program, doctors and dieticians will review the exercise and diet records, results of investigations, and modify treatment according to patient response, according to standard care guidelines, aiming for at least 5% weight loss.

03

Conditions studied

  • Obesity and Type 2 Diabetes
  • NAFLD - Non-Alcoholic Fatty Liver Disease
  • Hypertension
  • Dyslipidaemia
  • Telemedicine

Keywords

  • obesity
  • type 2 diabetes
  • masld
  • nafld
  • telecare
  • telemedicine
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 21-70
  • > 27.5 kg/m2
  • Waist circumference > 90 cm in men or 80 cm in women
  • Suboptimal control of type 2 diabetes ( > 6.5%) AND/OR MASLD (as defined on radiological or histological evidence of hepatic steatosis in the absence of other chronic liver disease)

Exclusion criteria

Exclusion Criteria:

  • Men who drink > 21 units/week and women who drink > 14 units/week of alcohol
  • Participants previously on weight-lowering medications (however if they are keen to participate, there will be a minimum of 3 months before participation)
  • Illness with of less than 6 months
  • Inability to comply with written instructions in English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Control

    The standard F2F structured weight management program consists of 4 doctor and 4 dietician consults over 26 weeks, at 2-4 weekly intervals in the first 3 months, and 6-8 weeks in the next 3 months. At the baseline visit, participants are provided with an aerobic and resistance exercise prescription individualized to each subject's fitness and comorbidities to target at least 180 minutes/week of moderate-intensity physical activity (with exercise on at least 3 days/week), and dietary advice based on a calorie-deficit diet (400-600 kilocalories less than the calculated daily caloric requirement, based on the Mifflin-St Jeor equation) which emphasizes reduction in sugar-sweetened beverages, refined carbohydrates and saturated fats. Subjects will be provided with a list of fitness resources such as gyms and fitness corners with advice on use of the equipment, and specific guidance on increasing intensity and duration of exercise and monitoring for injury.

    Behavioral: Standard of care weight management program

  • Experimental
    OneSTOP program

    The OneSTOP program will incorporate at least 50% (4 out of 8 sessions) of the doctor and dietician consults over the 26-week study as teleconsults, which may be scheduled as joint or asynchronous consults. The exercise prescription and calorie restriction will be tailored to each subject's individual needs as in the F2F structured weight management program in the control group. In addition, participants will be taught to use the EMPOWER app will be used to enable them to upload their weight, blood pressure and glucose, food and exercise duration records. The app also has the capability to co-ordinate visits and investigations, deliver intelligent health nudges and reminders on adherence to treatment which can be individualized to their progress, and provide information on their conditions curated by their doctors and dieticians.

    Behavioral: OneSTOP program

Interventions

  • BehavioralOneSTOP program

    The OneSTOP program will incorporate at least 50% (4 out of 8 sessions) of the doctor and dietician consults over the 26-week study as teleconsults, which may be scheduled as joint or asynchronous consults. The exercise prescription and calorie restriction will be tailored to each subject's individual needs as in the F2F structured weight management program in the control group. In addition, participants will be taught to use the EMPOWER app will be used to enable them to upload their weight, blood pressure and glucose, food and exercise duration records. The app also has the capability to co-ordinate visits and investigations, deliver intelligent health nudges and reminders on adherence to treatment which can be individualized to their progress, and provide information on their conditions curated by their doctors and dieticians.

  • BehavioralStandard of care weight management program

    The standard face-to-face weight management program consists of 4 doctor and 4 dietician consults over 26 weeks, at 2-4 weekly intervals in the first 3 months, and 6-8 weeks in the next 3 months. At the baseline visit, participants are provided with an aerobic and resistance exercise prescription individualized to each subject's fitness and comorbidities to target at least 180 minutes/week of moderate-intensity physical activity (with exercise on at least 3 days/week), and dietary advice based on a calorie-deficit diet (400-600 kilocalories less than the calculated daily caloric requirement, based on the Mifflin-St Jeor equation) which emphasizes reduction in sugar-sweetened beverages, refined carbohydrates and saturated fats. Subjects will be provided with a list of fitness resources such as gyms and fitness corners with advice on use of the equipment, and specific guidance on increasing intensity and duration of exercise and monitoring for injury.

06

What researchers measure

Primary outcomes

  1. weight loss

    percentage reduction in weight from baseline

    Time frame: 26 weeks

Secondary outcomes

  1. percentage of subjects with reduction in weight at least 5%

    percentage of subjects with reduction in weight at least 5%

    Time frame: 26 weeks

  2. improvement in glycaemic control

    reduction in HbA1c

    Time frame: 26 weeks

  3. improvement in MASLD

    reduction in severity of MASLD using liver function tests and imaging to measure hepatic steatosis and fibrosis

    Time frame: 26 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data of patients is confidential.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Feb 2027, 21 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 21 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 21, 2025
StartEst.
May 1, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Aug 31, 2027
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06890169
Responsible party
Joan Khoo Joo Ching (Clinical Associate Professor, Changi General Hospital) — Principal investigator
First posted
Mar 21, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Mar 21, 2025

Study contacts

Joan Khoo, MBBS, FRCP
Contact
joan.khoo.j.c@singhealth.com.sg
+65 69365641
Joan Khoo, MBBS, FRCP
principal investigator · Changi General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion